298 patents
Page 15 of 15
Utility
Dosing Regimen for the Treatment of PI3K Related Disorders
4 Dec 19
The present application provides methods of treating PI3Kδ related disorders using pyrazolopyrimidine derivatives.
Krishnaswamy Yeleswaram, Albert Assad, Xuejun Chen
Filed: 30 May 19
Utility
Pyridine and Pyridimine Compounds As PI3K-GAMMA Inhibitors
27 Nov 19
Richard B. Sparks, Stacey Shepard, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang, Nikoo Falahatpisheh
Filed: 28 Mar 19
Utility
Tricyclic Heterocyclic Compounds As Sting Activators
27 Nov 19
The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
Filed: 23 May 19
Utility
Pyrazolopyridine Compounds and Uses Thereof
13 Nov 19
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Alexander Sokolsky, Oleg Vechorkin, Kai Liu, Jun Pan, Wenqing Yao, Qinda Ye
Filed: 21 Jul 19
Utility
Heterocyclic Compounds As Immunomodulators
13 Nov 19
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Filed: 9 May 19
Utility
Salts of an LSD1 Inhibitor
13 Nov 19
The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.
Yongchun Pan, Wayne Han, Ganfeng Cao, Zhongjiang Jia, Jiacheng Zhou
Filed: 19 Jun 19
Utility
Pyrrole Tricyclic Compounds As A2A / A2B Inhibitors
6 Nov 19
Xiaozhao Wang, Peter Niels Carlsen, Chunhong He, Taisheng Huang
Filed: 7 Apr 19
Utility
Solid Forms of an FGFR Inhibitor and Processes for Preparing the Same
6 Nov 19
The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4, 7-tetrahydro-2H-pyrrolo[3′,2′: 5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
William Frietze, Zhongjiang Jia, Ming Tao, Dengjin Wang, Jiacheng Zhou, Qun Li, Timothy C. Burn, Phillip C. Liu
Filed: 2 May 19
Utility
Treatment of Hidradenitis Suppurativa Using Jak Inhibitors
30 Oct 19
The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.
Michael D. Howell, Paul Smith
Filed: 28 Mar 19
Utility
Biomarkers for Graft-versus-host Disease
30 Oct 19
Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor.
Michael D. Howell, Hao Liu, Michael A. Pratta
Filed: 10 Apr 19
Utility
Pyrazolopyridine Compounds and Uses Thereof
16 Oct 19
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
Filed: 26 Jun 19
Utility
Benzimidazole and Indole Compounds and Uses Thereof
16 Oct 19
Joshua Hummel, Minh Nguyen, Alexander Sokolsky, Oleg Vechorkin, Qinda Ye, Wenqing Yao
Filed: 11 Apr 19
Utility
Salts and Processes of Preparing a PI3K Inhibitor
9 Oct 19
The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3Kδ), as well as a salt form and intermediates related thereto.
Lei Qiao, Lingkai Weng, David Meloni, Zhongjiang Jia, Jianji Wang, Jiacheng Zhou
Filed: 20 Jun 19
Utility
Formulations of an LSD1 Inhibitor
9 Oct 19
The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer.
William L. Rocco, Ying Liu, Mei Li, Tanvi Shah, Huifang Wu
Filed: 7 Nov 18
Utility
Amorphous Solid Form of a Bet Protein Inhibitor
2 Oct 19
The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
Filed: 28 May 19
Utility
Heterocyclic Compounds As Immunomodulators
2 Oct 19
Liangxing Wu, Jingwei Li, Wenqing Yao
Filed: 28 Mar 19
Utility
Heterocyclylamines As PI3K Inhibitors
2 Oct 19
Richard B. Sparks, Andrew P. Combs, Brent Douty, Yun-Long Li, Song Mei, Eddy W. Yue
Filed: 18 Jun 19
Utility
1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase
2 Oct 19
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
Filed: 18 Jun 19